Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
adverse events
hepatocellular carcinoma
lenvatinib
predictive factors
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
02
07
2021
received:
25
05
2021
accepted:
08
07
2021
pubmed:
13
7
2021
medline:
4
3
2022
entrez:
12
7
2021
Statut:
ppublish
Résumé
Lenvatinib is a standard of care option in first-line therapy of advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with HCC treated with lenvatinib, a possible association between occurrence and grading of adverse events (AEs) and outcome. We performed a retrospective analysis of 606 Japanese and Italian patients treated with lenvatinib in first-line setting and investigated the possible correlation between the onset of AEs, toxicity grade (G) and outcome measures such as overall survival (OS) and progression-free survival (PFS). The appearance of arterial hypertension G ≥ 2 independently predicted prolonged OS [hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.46-0.93, P = .0188], whereas decreased appetite G ≥ 2 independently predicted decreased OS (HR 1.70, 95% CI 1.25-2.32, P = .0007) by multivariate analysis. Appearance of hand-foot skin reaction independently predicted prolonged PFS (HR 0.72, 95% CI 0.56-0.93, P = .0149), whereas decreased appetite G ≥ 2 predicted decreased PFS (HR 1.36, 95% CI 1.04-1.77, P = .0277). Our main findings are that the occurrence of arterial hypertension G ≥ 2 is a predictor of longer survival, whereas decreased appetite G ≥ 2 predicts for a poor prognosis. A careful management of AEs under lenvatinib treatment for HCC is required, to improve patients' quality of life, minimize the need for treatment discontinuation and achieve optimal outcome.
Sections du résumé
BACKGROUND AND AIM
Lenvatinib is a standard of care option in first-line therapy of advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with HCC treated with lenvatinib, a possible association between occurrence and grading of adverse events (AEs) and outcome.
METHODS
We performed a retrospective analysis of 606 Japanese and Italian patients treated with lenvatinib in first-line setting and investigated the possible correlation between the onset of AEs, toxicity grade (G) and outcome measures such as overall survival (OS) and progression-free survival (PFS).
RESULTS
The appearance of arterial hypertension G ≥ 2 independently predicted prolonged OS [hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.46-0.93, P = .0188], whereas decreased appetite G ≥ 2 independently predicted decreased OS (HR 1.70, 95% CI 1.25-2.32, P = .0007) by multivariate analysis. Appearance of hand-foot skin reaction independently predicted prolonged PFS (HR 0.72, 95% CI 0.56-0.93, P = .0149), whereas decreased appetite G ≥ 2 predicted decreased PFS (HR 1.36, 95% CI 1.04-1.77, P = .0277).
CONCLUSIONS
Our main findings are that the occurrence of arterial hypertension G ≥ 2 is a predictor of longer survival, whereas decreased appetite G ≥ 2 predicts for a poor prognosis. A careful management of AEs under lenvatinib treatment for HCC is required, to improve patients' quality of life, minimize the need for treatment discontinuation and achieve optimal outcome.
Substances chimiques
Phenylurea Compounds
0
Quinolines
0
lenvatinib
EE083865G2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2997-3008Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2:16018.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-1173.
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905.
Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960-2970.
Alsina A, Kudo M, Vogel A, et al. Effects of subsequent systemic anticancer medication following first-line lenvatinib: A post hoc responder analysis from the Phase 3 REFLECT Study in unresectable hepatocellular carcinoma. Liver Cancer. 2020;9(1):93-104.
Shimose S, Kawaguchi T, Tanaka M, et al. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett. 2020;20(3):2257-2265.
Lee J, Sung PS, Yang H, et al. A real-world comparative analysis of lenvatinib and sorafenib as a salvage therapy for transarterial treatments in unresectable HCC. J Clin Med. 2020;9(12):4121.
Casadei-Gardini A, Scartozzi M, Tada T, et al. Lenvatinib versus Sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver Int. 2021;41:1389-1397.
Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh a liver function: A proof-of-concept study. Cancers (Basel). 2019;11(8):1084.
Kudo M, Han K-H, Ye S-L, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer. 2020;9(3):245-260.
Sung MW, Finn RS, Qin S, et al. Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT). J Clin Oncol. 201937(4_suppl):317.
Shomura M, Okabe H, Sato E, et al. Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy. Cancers (Basel). 2020;12(11):1-14.
Ohki T, Sato K, Kondo M, et al. Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma. Liver Res. 2020;4(4):199-205.
Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: Hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013;36:319-324.
Gardini AC, Scarpi E, Marisi G, et al. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group. Oncotarget. 2016;7(12):15243-15251.
Wirth LJ, Tahara M, Robinson B, et al. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018;124(11):2365-2372.
Shimose S, Iwamoto H, Niizeki T, et al. Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: A multicenter retrospective study. Cancers (Basel). 2020;12(7):1-15.
Budolfsen C, Faber J, Grimm D, et al. Tyrosine kinase inhibitor-induced hypertension: Role of hypertension as a biomarker in cancer treatment. Curr Vasc Pharmacol. 2019;17(6):618-634.
Saito K, Fujii H, Kono K, et al. Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib. Clin Kidney J. 2021;14(1):325-331.
Suyama K, Tomiguchi M, Takeshita T, et al. Factors involved in early lenvatinib dose reduction: A retrospective analysis. Med Oncol. 2018;35(3).
Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019;77:20-28.
Sueta D, Suyama K, Sueta A, et al. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. Atherosclerosis. 2017;260:116-120.
Ikeda M, Okusaka T, Mitsunaga S, et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2016;22(6):1385-1394.
Koyama N, Saito K, Nishioka Y, et al. Pharmacodynamic change in plasma angiogenic proteins: A dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer. 2014;14(1):530.
David S, Kümpers P, Lukasz A, Kielstein JT, Haller H, Fliser D. Circulating angiopoietin-2 in essential hypertension: Relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/ pravastatin. J Hypertens. 2009;27(8):1641-1647.
Shigesawa T, Suda G, Kimura M, et al. Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open. 2020;4(5):880-888.
Chuma M, Uojima H, Numata K, et al. Early changes in circulating FGF19 and ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma. Cancers (Basel). 2020;12(2):293.
Shigesawa T, Suda G, Kimura M, et al. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS One. 2021;16(3):e0247728.
Casadei-Gardini A, Marisi G, Dadduzio V, et al. Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clin Cancer Res. 2020;26(17):4485-4493.
Goh MJ, Oh JH, Park Y, et al. Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea. Liver Cancer. 2021;10(1):52-62.
Ohki T, Sato K, Kondo M, et al. Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib: A multicenter retrospective study. Drugs - Real World Outcomes. 2020;7(2):141-149.
Ogushi K, Chuma M, Uojima H, et al. Safety and efficacy of lenvatinib treatment in Child-Pugh a and b patients with unresectable hepatocellular carcinoma in clinical practice: A multicenter analysis. Clin Exp Gastroenterol. 2020;13:385-396.
Hatanaka T, Kakizaki S, Nagashima T, et al. Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. Hepatol Res. 2020;50(3):382-395.
Hiraoka A, Kumada T, Atsukawa M, et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med. 2019;8(8):3719-3728.
Hiraoka A, Kumada T, Kariyama K, et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol. 2020;36(7):1812-1819.
Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med. 2019;8(1):137-146.
Rinninella E, Cintoni M, Raoul P, et al. Skeletal muscle loss during multikinase inhibitors therapy: Molecular pathways, clinical implications, and nutritional challenges. Nutrients. 2020;12:1-17.
Tada T, Kumada T, Hiraoka A, et al. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. Hepatol Res. 2020;50(1):75-83.
Zhang W, Feng LJ, Teng F, Li YH, Zhang X, Ran YG. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: An up-to-date meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2020;13(3):311-320.
Ikeda M, Kobayashi M, Tahara M, Kaneko S. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Expert Opin Drug Saf. 2018;17(11):1095-1105.
Zhang H, Zhang X, Zhu X, et al. The impact of renal impairment on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Cancer Control. 2020;27(1):1073274820977143.
Shimamura Y, Abe K, Maeda T, Matsui T, Ishiguro A, Takizawa H. Association between renal adverse effects and mortality in patients with hepatocellular carcinoma treated with lenvatinib. In Vivo. 2021;35(3):1647-1653.
Hata K, Suetsugu K, Egashira N, et al. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol. 2020;86(6):803-813.
Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: An analysis of Japanese subset. J Gastroenterol. 2020;55(1):113-122.
Eso Y, Nakano S, Mishima M, et al. Mac-2 binding protein glycosylation isomer predicts tolerability and clinical outcome of lenvatinib therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2021;28(6):498-507.
Kirino S, Tsuchiya K, Kurosaki M, et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One. 2020;15(4):e0231828.